<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">35014217</PMID><DateCompleted><Year>2022</Year><Month>03</Month><Day>16</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>16</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2328-9503</ISSN><JournalIssue CitedMedium="Internet"><Volume>9</Volume><Issue>1</Issue><PubDate><Year>2022</Year><Month>Jan</Month></PubDate></JournalIssue><Title>Annals of clinical and translational neurology</Title><ISOAbbreviation>Ann Clin Transl Neurol</ISOAbbreviation></Journal><ArticleTitle>A Phase 1 study of GDC-0134, a dual leucine zipper kinase inhibitor, in ALS.</ArticleTitle><Pagination><StartPage>50</StartPage><EndPage>66</EndPage><MedlinePgn>50-66</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/acn3.51491</ELocationID><Abstract><AbstractText Label="OBJECTIVE">Dual leucine zipper kinase (DLK), which regulates the c-Jun N-terminal kinase pathway involved in axon degeneration and apoptosis following neuronal injury, is a potential therapeutic target in amyotrophic lateral sclerosis (ALS). This first-in-human study investigated safety, tolerability, and pharmacokinetics (PK) of oral GDC-0134, a small-molecule DLK inhibitor. Plasma neurofilament light chain (NFL) levels were explored in GDC-0134-treated ALS patients and DLK conditional knockout (cKO) mice.</AbstractText><AbstractText Label="METHODS">The study included placebo-controlled, single and multiple ascending-dose (SAD; MAD) stages, and an open-label safety expansion (OLE) with adaptive dosing for up to 48&#x2009;weeks.</AbstractText><AbstractText Label="RESULTS">Forty-nine patients were enrolled. GDC-0134 (up to 1200&#x2009;mg daily) was well tolerated in the SAD and MAD stages, with no serious adverse events (SAEs). In the OLE, three study drug-related SAEs occurred: thrombocytopenia, dysesthesia (both Grade 3), and optic ischemic neuropathy (Grade 4); Grade &#x2264;2 sensory neurological AEs led to dose reductions/discontinuations. GDC-0134 exposure was dose-proportional (median half-life&#x2009;=&#x2009;84&#x2009;h). Patients showed GDC-0134 exposure-dependent plasma NFL elevations; DLK cKO mice also exhibited plasma NFL compared to wild-type littermates.</AbstractText><AbstractText Label="INTERPRETATION">This trial characterized GDC-0134 safety and PK, but no adequately tolerated dose was identified. NFL elevations in GDC-0134-treated patients and DLK cKO mice raised questions about interpretation of biomarkers affected by both disease and on-target drug effects. The safety profile of GDC-0134 was considered unacceptable and led to discontinuation of further drug development for ALS. Further work is necessary to understand relationships between neuroprotective and potentially therapeutic effects of DLK knockout/inhibition and NFL changes in patients with ALS.</AbstractText><CopyrightInformation>&#xa9; 2022 Genentech, Inc. Annals of Clinical and Translational Neurology published by Wiley Periodicals LLC on behalf of American Neurological Association.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Katz</LastName><ForeName>Jonathan S</ForeName><Initials>JS</Initials><AffiliationInfo><Affiliation>Forbes Norris MDA/ALS Research Center, California Pacific Medical Center, San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rothstein</LastName><ForeName>Jeffrey D</ForeName><Initials>JD</Initials><AffiliationInfo><Affiliation>Johns Hopkins Hospital, Baltimore, Maryland, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cudkowicz</LastName><ForeName>Merit E</ForeName><Initials>ME</Initials><AffiliationInfo><Affiliation>Sean M. Healey and AMG Center for ALS, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Genge</LastName><ForeName>Angela</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Montreal Neurological Institute &amp; Hospital, Montreal, QC, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Oskarsson</LastName><ForeName>Bj&#xf6;rn</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Mayo Clinic, Jacksonville, Florida, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hains</LastName><ForeName>Avis B</ForeName><Initials>AB</Initials><AffiliationInfo><Affiliation>Genentech, Inc., South San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Chen</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Genentech, Inc., South San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Galanter</LastName><ForeName>Joshua</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Genentech, Inc., South San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Burgess</LastName><ForeName>Braydon L</ForeName><Initials>BL</Initials><AffiliationInfo><Affiliation>Genentech, Inc., South San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cho</LastName><ForeName>William</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Genentech, Inc., South San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kerchner</LastName><ForeName>Geoffrey A</ForeName><Initials>GA</Initials><AffiliationInfo><Affiliation>F. Hoffmann-La Roche, Ltd., Basel, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yeh</LastName><ForeName>Felix L</ForeName><Initials>FL</Initials><AffiliationInfo><Affiliation>Genentech, Inc., South San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ghosh</LastName><ForeName>Arundhati Sengupta</ForeName><Initials>AS</Initials><AffiliationInfo><Affiliation>Genentech, Inc., South San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cheeti</LastName><ForeName>Sravanthi</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Genentech, Inc., South San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brooks</LastName><ForeName>Logan</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Genentech, Inc., South San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Honigberg</LastName><ForeName>Lee</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Genentech, Inc., South San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Couch</LastName><ForeName>Jessica A</ForeName><Initials>JA</Initials><AffiliationInfo><Affiliation>Genentech, Inc., South San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rothenberg</LastName><ForeName>Michael E</ForeName><Initials>ME</Initials><AffiliationInfo><Affiliation>Genentech, Inc., South San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brunstein</LastName><ForeName>Flavia</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Genentech, Inc., South San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sharma</LastName><ForeName>Khema R</ForeName><Initials>KR</Initials><AffiliationInfo><Affiliation>University of Miami Hospital (CRC), Miami, Florida, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van den Berg</LastName><ForeName>Leonard</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>UMC Utrecht, Utrecht, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Berry</LastName><ForeName>James D</ForeName><Initials>JD</Initials><AffiliationInfo><Affiliation>Neurological Clinical Research Institute, Boston, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Glass</LastName><ForeName>Jonathan D</ForeName><Initials>JD</Initials><Identifier Source="ORCID">0000-0002-3295-4971</Identifier><AffiliationInfo><Affiliation>Emory University School of Medicine, Atlanta, Georgia, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><Agency>Genentech, Inc.</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D017426">Clinical Trial, Phase I</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>01</Month><Day>10</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Ann Clin Transl Neurol</MedlineTA><NlmUniqueID>101623278</NlmUniqueID><ISSNLinking>2328-9503</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016900">Neurofilament Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D047428">Protein Kinase Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C044882">neurofilament protein L</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.25</RegistryNumber><NameOfSubstance UI="D020930">MAP Kinase Kinase Kinases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.25</RegistryNumber><NameOfSubstance UI="C090757">mitogen-activated protein kinase kinase kinase 12</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004305" MajorTopicYN="N">Dose-Response Relationship, Drug</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020930" MajorTopicYN="N">MAP Kinase Kinase Kinases</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="Y">antagonists &amp; inhibitors</QualifierName><QualifierName UI="Q000172" MajorTopicYN="N">deficiency</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018345" MajorTopicYN="N">Mice, Knockout</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016900" MajorTopicYN="N">Neurofilament Proteins</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017063" MajorTopicYN="N">Outcome Assessment, Health Care</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D047428" MajorTopicYN="N">Protein Kinase Inhibitors</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName><QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>JSK: Nothing to disclose. JDR: Nothing to disclose. MEC: Consultant for Avexis, consultant for Orion, consultant for Lilly, consultant for Biohaven, consultant for MT Pharma, consultant for Revalasio, consultant for Pontifex, consultant for Denali, consultant for Biogen, consultant for Pharm NEXT, consultant for Treeway, consultant for Takeda, consultant for Aclipse, consultant for Sunovian, consultant for Anelixis, consultant for Cytokinetics, consultant for Disarm, consultant for ALS Pharma, consultant for RRD, consultant for Immunity Pharma, consultant for Helixsmith, consultant for Wave, consultant for Transposon, consultant for Quralis. AG: Other from Quralis, other from Mitsubishi Tanabe Pharma America, other from Sanofi Genzyme, other from AL&#x2010;S Pharma, other from Biogen, other from Novartis, other from Uniqure, other from Affinia, other from Apellis, other from Avenix, other from Alexion, other from Wave Life Sciences, other from Roche, other from Cytokinetics, other from Orion, other from Medtronic, other from Anaelixis, other from Viela, other from ArgenX, other from BMS, other from Sanofi Genzyme, other from Grifols, other from Ionis, other from Lily, other from Machinova, other from Novartis, other from Orphazyme, other from Pfizer, other from Ra Pharmaseuticals, other from Teva, other from UCB, during the conduct of the study. BO: Grants from Genentech, A Member of the Roche Group, during the conduct of the study; grants and personal fees from Biogen, grants from Eisai, grants and personal fees from Mitsubishi Tanabe, grants and personal fees from Medicinova, grants from AZ Therapeutics, personal fees from Biohaven, personal fees from Tsumura, outside the submitted work. ABH: Employee of Genentech, Inc. and shareholder in F. Hoffmann&#x2010;La Roche, Ltd. CC: Employee of Genentech, Inc. and shareholder in F. Hoffmann&#x2010;La Roche, Ltd. JG: Employee of Genentech, Inc. and shareholder in F. Hoffmann&#x2010;La Roche, Ltd. BLB: Employee of Genentech, Inc. and shareholder in F. Hoffmann&#x2010;La Roche, Ltd. WC: Employee of Genentech, Inc. and shareholder in F. Hoffmann&#x2010;La Roche, Ltd. GAK: Employee of F. Hoffmann&#x2010;La Roche, Ltd. FLY: Employee of Genentech, Inc. and shareholder in F. Hoffmann&#x2010;La Roche, Ltd. ASG: Employee of Genentech, Inc. and shareholder in F. Hoffmann&#x2010;La Roche, Ltd. SC: Employee of Genentech, Inc. and shareholder in F. Hoffmann&#x2010;La Roche, Ltd. LB: Employee of Genentech, Inc. and shareholder in F. Hoffmann&#x2010;La Roche, Ltd. LH: Employee of Genentech, Inc. and shareholder in F. Hoffmann&#x2010;La Roche, Ltd. JAC: Employee of Genentech, Inc. and shareholder in F. Hoffmann&#x2010;La Roche, Ltd. MER: Employee of Genentech, Inc. and shareholder in F. Hoffmann&#x2010;La Roche, Ltd. FB: Employee of Genentech, Inc. and shareholder in F. Hoffmann&#x2010;La Roche, Ltd. KRS: Nothing to disclose. LvdB: Nothing to disclose. JDB: Grants from Genentech, during the conduct of the study; personal fees from Biogen, personal fees from Clene Nanomedicine, grants from Alexion, grants from Biogen, grants from MT Pharma of America, grants from Anelixis Therapeutics, grants from Brainstorm Cell Therapeutics, grants from nQ Medical, grants from NINDS, grants from Muscular Dystrophy Association, grants from ALS One, grants from Amylyx Therapeutics, personal fees from MT Pharma Holdings of America, grants from ALS Association, grants from ALS Finding A Cure, outside the submitted work. JDG: Emory University was a clinical trial site during the conduct of the study.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>12</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>12</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>1</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>3</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>1</Month><Day>11</Day><Hour>7</Hour><Minute>17</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35014217</ArticleId><ArticleId IdType="pmc">PMC8791798</ArticleId><ArticleId IdType="doi">10.1002/acn3.51491</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Mehta P, Kaye W, Raymond J, et&#xa0;al. Prevalence of amyotrophic lateral sclerosis &#x2014; United States, 2014. MMWR Morb Mortal Wkly Rep. 2018;67:216&#x2010;218.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5858037</ArticleId><ArticleId IdType="pubmed">29470458</ArticleId></ArticleIdList></Reference><Reference><Citation>Kiernan MC, Vucic S, Cheah BC, et&#xa0;al. Amyotrophic lateral sclerosis. Lancet. 2011;377:942&#x2010;955.</Citation><ArticleIdList><ArticleId IdType="pubmed">21296405</ArticleId></ArticleIdList></Reference><Reference><Citation>Swinnen B, Robberecht W. The phenotypic variability of amyotrophic lateral sclerosis. Nat Rev Neurol. 2014;10:661&#x2010;670.</Citation><ArticleIdList><ArticleId IdType="pubmed">25311585</ArticleId></ArticleIdList></Reference><Reference><Citation>Renton AE, Chi&#xf2; A, Traynor BJ. State of play in amyotrophic lateral sclerosis genetics. Nat Neurosci. 2014;17:17&#x2010;23.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4544832</ArticleId><ArticleId IdType="pubmed">24369373</ArticleId></ArticleIdList></Reference><Reference><Citation>Mathis S, Goizet C, Soulages A, et&#xa0;al. Genetics of amyotrophic lateral sclerosis: a review. J Neurol Sci. 2019;399:217&#x2010;226.</Citation><ArticleIdList><ArticleId IdType="pubmed">30870681</ArticleId></ArticleIdList></Reference><Reference><Citation>Cook C, Petrucelli L. Genetic convergence brings clarity to the enigmatic red line in ALS. Neuron. 2019;101:1057&#x2010;1069.</Citation><ArticleIdList><ArticleId IdType="pubmed">30897357</ArticleId></ArticleIdList></Reference><Reference><Citation>Lacomblez L, Bensimon G, Leigh PN, et&#xa0;al. Amyotrophic Lateral Sclerosis/Riluzole Study Group II. Dose&#x2010;ranging study of riluzole in amyotrophic lateral sclerosis. Lancet. 1996;347:1425&#x2010;1431.</Citation><ArticleIdList><ArticleId IdType="pubmed">8676624</ArticleId></ArticleIdList></Reference><Reference><Citation>Writing Group; Edaravone (MCI&#x2010;186) ALS 19 Study Group . Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double&#x2010;blind, placebo&#x2010;controlled trial. Lancet Neurol. 2017;16:505&#x2010;512.</Citation><ArticleIdList><ArticleId IdType="pubmed">28522181</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghosh AS, Wang B, Pozniak CD, et&#xa0;al. DLK induces developmental neuronal degeneration via selective regulation of proapoptotic JNK activity. J Cell Biol. 2011;194:751&#x2010;764.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3171129</ArticleId><ArticleId IdType="pubmed">21893599</ArticleId></ArticleIdList></Reference><Reference><Citation>Pozniak CD, Sengupta Ghosh A, et&#xa0;al. Dual leucine zipper kinase is required for excitotoxicity&#x2010;induced neuronal degeneration. J Exp Med. 2013;210:2553&#x2010;2567.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3832926</ArticleId><ArticleId IdType="pubmed">24166713</ArticleId></ArticleIdList></Reference><Reference><Citation>Watkins TA, Wang B, Huntwork&#x2010;Rodriguez S, et&#xa0;al. DLK initiates a transcription program that couples apoptotic and regenerative responses to axonal injury. Proc Natl Acad Sci USA. 2013;110:4039&#x2010;4044.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3593899</ArticleId><ArticleId IdType="pubmed">23431164</ArticleId></ArticleIdList></Reference><Reference><Citation>Wlaschin JJ, Gluski JM, Nguyen E, et&#xa0;al. Dual leucine zipper kinase is required for mechanical allodynia and microgliosis after nerve injury. eLife. 2018;7:e33910.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6029846</ArticleId><ArticleId IdType="pubmed">29968565</ArticleId></ArticleIdList></Reference><Reference><Citation>Patel S, Cohen F, Dean BJ, et&#xa0;al. Discovery of dual leucine zipper kinase (DLK, MAP3K12) inhibitors with activity in neurodegeneration models. J Med Chem. 2015;58:401&#x2010;418.</Citation><ArticleIdList><ArticleId IdType="pubmed">25341110</ArticleId></ArticleIdList></Reference><Reference><Citation>Itoh A, Horiuchi M, Wakayama K, et&#xa0;al. ZPK/DLK, a mitogen&#x2010;activated protein kinase kinase kinase, is a critical mediator of programmed cell death of motoneurons. J Neurosci. 2011;31:7223&#x2010;7228.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3138193</ArticleId><ArticleId IdType="pubmed">21593306</ArticleId></ArticleIdList></Reference><Reference><Citation>Vlug AS, Teuling E, Haasdijk ED, et&#xa0;al. ATF3 expression precedes death of spinal motoneurons in amyotrophic lateral sclerosis&#x2010;SOD1 transgenic mice and correlates with c&#x2010;Jun phosphorylation, CHOP expression, somato&#x2010;dendritic ubiquitination and Golgi fragmentation. Eur J Neurosci. 2005;22:1881&#x2010;1894.</Citation><ArticleIdList><ArticleId IdType="pubmed">16262628</ArticleId></ArticleIdList></Reference><Reference><Citation>Le Pichon CE, Meilandt WJ, Dominguez S, et&#xa0;al. Loss of dual leucine zipper kinase signaling is protective in animal models of neurodegenerative disease. Sci Transl Med. 2017;9:eaag0394.</Citation><ArticleIdList><ArticleId IdType="pubmed">28814543</ArticleId></ArticleIdList></Reference><Reference><Citation>Hirai S, Cui de F, Miyata T, et&#xa0;al. The c&#x2010;Jun N&#x2010;terminal kinase activator dual leucine zipper kinase regulates axon growth and neuronal migration in the developing cerebral cortex. J Neurosci. 2006;26:11992&#x2010;12002.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6674859</ArticleId><ArticleId IdType="pubmed">17108173</ArticleId></ArticleIdList></Reference><Reference><Citation>Bacioglu M, Maia LF, Preische O, et&#xa0;al. Neurofilament light chain in blood and CSF as marker of disease progression in mouse models and in neurodegenerative diseases. Neuron. 2016;91:56&#x2010;66. doi:10.1016/j.neuron.2016.05.018</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2016.05.018</ArticleId><ArticleId IdType="pubmed">27292537</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu CH, Macdonald&#x2010;Wallis C, Gray E, et&#xa0;al. Neurofilament light chain: a prognostic biomarker in amyotrophic lateral sclerosis. Neurology. 2015;84:2247&#x2010;2257.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4456658</ArticleId><ArticleId IdType="pubmed">25934855</ArticleId></ArticleIdList></Reference><Reference><Citation>Poesen K, Van Damme P. Diagnostic and prognostic performance of neurofilaments in ALS. Front Neurol. 2019;9:1167. doi:10.3389/fneur.2018.01167</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fneur.2018.01167</ArticleId><ArticleId IdType="pmc">PMC6345692</ArticleId><ArticleId IdType="pubmed">30713520</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang F, Zhu Y, Hsiao&#x2010;Nakamoto J, et&#xa0;al. Longitudinal biomarkers in amyotrophic lateral sclerosis. Ann Clin Transl Neurol. 2020;7(7):1103&#x2010;1116. doi:10.1002/acn3.51078</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acn3.51078</ArticleId><ArticleId IdType="pmc">PMC7359115</ArticleId><ArticleId IdType="pubmed">32515902</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller T, Cudkowicz M, Shaw PJ, et&#xa0;al. Phase 1&#x2010;2 trial of antisense oligonucleotide tofersen for SOD1 ALS. N Engl J Med. 2020;383(2):109&#x2010;119. doi:10.1056/NEJMoa2003715</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2003715</ArticleId><ArticleId IdType="pubmed">32640130</ArticleId></ArticleIdList></Reference><Reference><Citation>Ludolph A, Drory V, Hardiman O, et&#xa0;al. A revision of the El Escorial criteria &#x2013; 2015. Amyotroph Lateral Scler Frontotemporal Degener. 2015;16:291&#x2010;292. doi:10.3109/21678421.2015.1049183</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/21678421.2015.1049183</ArticleId><ArticleId IdType="pubmed">26121170</ArticleId></ArticleIdList></Reference><Reference><Citation>
Division of Microbiology and Infectious Diseases (DMID)
. Adult Toxicity Table&#xa0;(Draft). National Institute of Allergy and Infectious Diseases. 2007. Accessed December 20, 2021. https://www.niaid.nih.gov/research/dmid&#x2010;safety&#x2010;reporting&#x2010;pharmacovigilance
</Citation></Reference><Reference><Citation>
Introductory guide for standardised MedDRA queries (SMQs), Version 23.0. International Council for Harmonisation. 2020. Accessed December 20, 2021. https://admin.new.meddra.org/sites/default/files/guidance/file/SMQ_intguide_23_0_English.pdf
</Citation></Reference><Reference><Citation>Cedarbaum JM, Stambler N, Malta E, et&#xa0;al. The ALSFRS&#x2010;R: a revised ALS functional rating scale that incorporates assessments of respiratory function. BDNF ALS Study Group (Phase III). J Neurol Sci. 1999;169:13&#x2010;21. doi:10.1016/s0022&#x2010;510x(99)00210&#x2010;5</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0022&#x2010;510x(99)00210&#x2010;5</ArticleId><ArticleId IdType="pubmed">10540002</ArticleId></ArticleIdList></Reference><Reference><Citation>Gordon PH, Cheng B, Salachas F, et&#xa0;al. Progression in ALS is not linear but is curvilinear. J Neurol. 2010;257:1713&#x2010;1717. doi:10.1007/s00415&#x2010;010&#x2010;5609&#x2010;1</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415&#x2010;010&#x2010;5609&#x2010;1</ArticleId><ArticleId IdType="pubmed">20532545</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson LN, Arnold AC. Incidence of nonarteritic and arteritic anterior ischemic optic neuropathy. Population&#x2010;based study in the state of Missouri and Los Angeles County, California. J Neuroophthalmol. 1994;14:38.</Citation><ArticleIdList><ArticleId IdType="pubmed">8032479</ArticleId></ArticleIdList></Reference><Reference><Citation>Arnold AC. Pathogenesis of nonarteritic anterior ischemic optic neuropathy. J Neuroophthalmol. 2003;23(2):157.</Citation><ArticleIdList><ArticleId IdType="pubmed">12782932</ArticleId></ArticleIdList></Reference><Reference><Citation>Avery R, Jabs DA, Wingard JR, et&#xa0;al. Optic disc edema after bone marrow transplantation. Possible role of cyclosporine toxicity. Ophthalmology. 1991;98:1294&#x2010;1301. doi:10.1016/s0161&#x2010;6420(91)32140&#x2010;7</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0161&#x2010;6420(91)32140&#x2010;7</ArticleId><ArticleId IdType="pubmed">1923369</ArticleId></ArticleIdList></Reference><Reference><Citation>Campbell UB, Walker AM, Gaffney M, et&#xa0;al. Acute nonarteritic anterior ischemic optic neuropathy and exposure to phosphodiesterase type 5 inhibitors. J Sex Med. 2015;12:139.</Citation><ArticleIdList><ArticleId IdType="pubmed">25358826</ArticleId></ArticleIdList></Reference><Reference><Citation>Nathoo NA, Etminan M, Mikelberg FS. Association between phosphodiesterase&#x2010;5 inhibitors and nonarteritic anterior ischemic optic neuropathy. J Neuroophthalmol. 2015;35:12.</Citation><ArticleIdList><ArticleId IdType="pubmed">25295683</ArticleId></ArticleIdList></Reference><Reference><Citation>Mimouni K, Lusky M, Kramer M, et&#xa0;al. Early isolated optic neuropathy caused by cyclosporine. Int Ophthalmol. 2019;39:853&#x2010;860. doi:10.1007/s10792&#x2010;018&#x2010;0886&#x2010;2</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10792&#x2010;018&#x2010;0886&#x2010;2</ArticleId><ArticleId IdType="pubmed">29532216</ArticleId></ArticleIdList></Reference><Reference><Citation>Benatar M, Zhang L, Wang L, et&#xa0;al. Validation of serum neurofilaments as prognostic and potential pharmacodynamic biomarkers for ALS. Neurology. 2020;95(1):e59&#x2010;e69. doi:10.1212/WNL.0000000000009559</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000009559</ArticleId><ArticleId IdType="pmc">PMC7371380</ArticleId><ArticleId IdType="pubmed">32385188</ArticleId></ArticleIdList></Reference><Reference><Citation>Sormani MP, Haering DA, Kropshofer H, et&#xa0;al. Blood neurofilament light as a potential endpoint in Phase 2 studies in MS. Ann Clin Transl Neurol. 2019;6(6):1081&#x2010;1089. doi:10.1002/acn3.795</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acn3.795</ArticleId><ArticleId IdType="pmc">PMC6562031</ArticleId><ArticleId IdType="pubmed">31211172</ArticleId></ArticleIdList></Reference><Reference><Citation>Proudfoot M, Jones A, Talbot K, et&#xa0;al. The ALSFRS as an outcome measure in therapeutic trials and its relationship to symptom onset. Amyotroph Lateral Scler Frontotemporal Degener. 2016;17:414&#x2010;425. doi:10.3109/21678421.2016.1140786</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/21678421.2016.1140786</ArticleId><ArticleId IdType="pmc">PMC4950444</ArticleId><ArticleId IdType="pubmed">26864085</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>